Lenalidomide (BioDeep_00000027051)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione

化学式: C13H13N3O3 (259.0956868)
中文名称: 来那度胺
谱图信息: 最多检出来源 Homo sapiens(blood) 2.17%

分子结构信息

SMILES: C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
InChI: InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)

描述信息

Lenalidomide (initially known as CC-5013 and marketed as Revlimid by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia]
C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent > C157388 - Immunomodulatory Imide Drug
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents
D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
D006133 - Growth Substances > D006131 - Growth Inhibitors
D007155 - Immunologic Factors
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS

同义名列表

11 个代谢物同义名

3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline; Celgene brand OF lenalidomide; Lenalidomide; IMiD3 CPD; Revlimid; CDC 501; CC-5013; Revimid; IMiD3



数据库引用编号

11 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Sichun Xiang, Rongbin Shen, Jingjing Xiang, Ni Zhu, Jianyou Gu, Jianping Shen, Yu Zhang, Hangping Ge. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy. Expert opinion on drug safety. 2024 May; 23(5):627-636. doi: 10.1080/14740338.2024.2327507. [PMID: 38456691]
  • Xiaoxiao Liang, Haiyan Shi, Kehong Bi, Saran Feng, Shixian Chen, Wei Zhao, Xin Huang. Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1. Scientific reports. 2024 01; 14(1):2577. doi: 10.1038/s41598-024-52460-2. [PMID: 38297024]
  • Haimin Chen, Haiqi Chen, Yan Zhou, Weiwei Xu, Jingjing Yu, Yao Xu, Fan Zhou. Comparative efficacy of novel-drugs combined therapeutic regimens on relapsed/refractory multiple myeloma: a network meta-analysis. Hematology (Amsterdam, Netherlands). 2023 Dec; 28(1):2225342. doi: 10.1080/16078454.2023.2225342. [PMID: 37343159]
  • Yiying Wei, Xinxin Xu, Minchuan Jiang, Yongxing Wang, Yang Zhou, Zhen Wang, Zhang Zhang, Fengtao Zhou, Ke Ding. Discovery of new Lenalidomide derivatives as potent and selective GSPT1 degraders. European journal of medicinal chemistry. 2023 Oct; 258(?):115580. doi: 10.1016/j.ejmech.2023.115580. [PMID: 37418973]
  • Jian Wu, Xiaobei Wang, Min Zhang, Parker Mathews, Yubin Kang. RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect. Cells. 2023 08; 12(15):. doi: 10.3390/cells12151993. [PMID: 37566072]
  • Bin Wang, Wanting Qiang, Jia Yi, Shouhong Gao, Bosu Meng, Yuhui Mu, Bolong Wang, Zhipeng Wang, Xia Tao. Simultaneous quantification of thalidomide, lenalidomide and pomadomide in plasma by LC-MS/MS. Journal of pharmacological and toxicological methods. 2023 Mar; 120(?):107250. doi: 10.1016/j.vascn.2023.107250. [PMID: 36627002]
  • Shangjin Yin, Kuangguo Zhou, Zhiqiong Wang, Duanhao Gong, Wei Huang. Coexistence of primary mediastinal MALT lymphoma and multiple myeloma like POEMS syndrome: A case report and literature review. Medicine. 2023 Jan; 102(4):e32801. doi: 10.1097/md.0000000000032801. [PMID: 36705370]
  • G Mele, N Cascavilla, N Di Renzo, A Guarini, P Mazza, L Melillo, V Pavone, G Tarantini, P Curci, A P Falcone, C Germano, A Mele, G Palazzo, G Palumbo, G Reddiconto, B Rossini, G Specchia, P Musto, D Pastore. Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'. Annals of hematology. 2022 Aug; 101(8):1727-1739. doi: 10.1007/s00277-022-04857-0. [PMID: 35587825]
  • S Vincent Rajkumar. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. American journal of hematology. 2022 Aug; 97(8):1086-1107. doi: 10.1002/ajh.26590. [PMID: 35560063]
  • Brad Rybinski, Aaron P Rapoport, Ashraf Z Badros, Nancy Hardy, Mehmet Kocoglu. Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era. Clinical lymphoma, myeloma & leukemia. 2022 Aug; 22(8):e716-e729. doi: 10.1016/j.clml.2022.03.013. [PMID: 35504807]
  • Francesca Cottini, Jose Rodriguez, Tiffany Hughes, Nidhi Sharma, Ling Guo, Gerard Lozanski, Bei Liu, Emanuele Cocucci, Yiping Yang, Don Benson. Redefining CD56 as a Biomarker and Therapeutic Target in Multiple Myeloma. Molecular cancer research : MCR. 2022 07; 20(7):1083-1095. doi: 10.1158/1541-7786.mcr-21-0828. [PMID: 35380709]
  • Erin G Reid, Kelly Shimabukuro, Page Moore, Richard F Ambinder, Jack D Bui, Semi Han, Otoniel Martínez-Maza, Dirk P Dittmer, David Aboulafia, Elizabeth Yu Chiao, Toby Maurer, Robert Baiocchi, Ronald Mitsuyasu, William Wachsman. AMC-070: Lenalidomide Is Safe and Effective in HIV-Associated Kaposi Sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 06; 28(12):2646-2656. doi: 10.1158/1078-0432.ccr-21-0645. [PMID: 35247913]
  • Nizar J Bahlis, David S Siegel, Gary J Schiller, Christy Samaras, Michael Sebag, Jesus Berdeja, Siddhartha Ganguly, Jeffrey Matous, Kevin Song, Christopher S Seet, Mirelis Acosta-Rivera, Michael Bar, Donald Quick, Bertrand Anz, Gustavo Fonseca, Weiyuan Chung, Kim Lee, Jorge Mouro, Amit Agarwal, Donna Reece. Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Leukemia & lymphoma. 2022 06; 63(6):1407-1417. doi: 10.1080/10428194.2022.2030477. [PMID: 35133221]
  • Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel-Dedieu, Bernard Sebastien, Hoai-Thu Thai, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Helgi van de Velde, Christine Veyrat-Follet, Dorothée Semiond. Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma. CPT: pharmacometrics & systems pharmacology. 2022 Jun; 11(6):766-777. doi: 10.1002/psp4.12789. [PMID: 35355430]
  • Shinichi Mizuno, Chigusa Kitayama, Shigeto Mashiko, Satoru Sanada. Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma. CEN case reports. 2022 05; 11(2):265-268. doi: 10.1007/s13730-021-00668-w. [PMID: 34817845]
  • Sean Bujarski, Christine Sutanto, Tanya M Spektor, Jennifer To, Regina A Swift, Tracy Green, Benjamin R Eades, Marsiye Emamy-Sadr, Eric Souther, James R Berenson. Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone. Hematological oncology. 2022 Apr; 40(2):243-248. doi: 10.1002/hon.2961. [PMID: 34982491]
  • Shiyun Cao, Shoukai Kang, Haibin Mao, Jiayu Yao, Liangcai Gu, Ning Zheng. Defining molecular glues with a dual-nanobody cannabidiol sensor. Nature communications. 2022 02; 13(1):815. doi: 10.1038/s41467-022-28507-1. [PMID: 35145136]
  • Fredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Wojciech Legiec, Luděk Pour, Ivan Špička, Tamas Masszi, Vadim Doronin, Jiri Minarik, Galina Salogub, Yulia Alekseeva, Antonio Lazzaro, Vladimir Maisnar, Gábor Mikala, Laura Rosiñol, Anna Marina Liberati, Argiris Symeonidis, Victoria Moody, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Nicolaas A Bakker, Roman Hájek, Maria-Victoria Mateos, Paul G Richardson, Pieter Sonneveld. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. The Lancet. Haematology. 2022 Feb; 9(2):e98-e110. doi: 10.1016/s2352-3026(21)00381-1. [PMID: 35032434]
  • Guoxing Zhao, Runhong Wei, Lei Feng, Yi Wu, Feng He, Mingxing Xiao, Zhi Cheng. Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature. Cancer immunology, immunotherapy : CII. 2022 Jan; 71(1):39-44. doi: 10.1007/s00262-021-02959-8. [PMID: 34003300]
  • Trevor Lane, Peter Hountras. A 65-Year-Old Man With Weight Loss, Peripheral Neuropathy, and Lower Extremity Swelling. Chest. 2022 01; 161(1):e29-e34. doi: 10.1016/j.chest.2021.07.054. [PMID: 35000714]
  • Andreas J Steck. Anti-MAG neuropathy: From biology to clinical management. Journal of neuroimmunology. 2021 12; 361(?):577725. doi: 10.1016/j.jneuroim.2021.577725. [PMID: 34610502]
  • Fabio Urbina, Ana C Puhl, Sean Ekins. Recent advances in drug repurposing using machine learning. Current opinion in chemical biology. 2021 12; 65(?):74-84. doi: 10.1016/j.cbpa.2021.06.001. [PMID: 34274565]
  • Liang Zhou, Xiangao Huang, Ruben Niesvizky, Zhongjian Pu, Guoqiang Xu. Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide. The Journal of pharmacology and experimental therapeutics. 2021 12; 379(3):303-309. doi: 10.1124/jpet.121.000818. [PMID: 34588172]
  • Meng Wang, Jing-Lan Zhang, Ding-Ming Wan, Rong Guo, Yuan-Dong Cheng, Zhong-Xing Jiang. [The Clinical Characteristics and Outcomes of the Patients with POEMS Syndrome]. Zhongguo shi yan xue ye xue za zhi. 2021 Oct; 29(5):1645-1648. doi: 10.19746/j.cnki.issn.1009-2137.2021.05.043. [PMID: 34627454]
  • Marta Krejci, Ludek Pour, Zdenek Adam, Viera Sandecka, Martin Stork, Sabina Sevcikova, Martin Krejci, Zdenka Knechtova, Zdenek Kral. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. Annals of hematology. 2021 Oct; 100(10):2541-2546. doi: 10.1007/s00277-021-04594-w. [PMID: 34309714]
  • Mariya Liyasova, Zac McDonald, Paul Taylor, Kathleen Gorospe, Xin Xu, Chenyu Yao, Qixin Liu, Liqiang Yang, Eshetu G Atenafu, Giovanni Piza, Bin Ma, Donna Reece, Suzanne Trudel. A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM). Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 09; 27(18):5028-5037. doi: 10.1158/1078-0432.ccr-21-0649. [PMID: 34210683]
  • Apor Hardi, Gergely Varga, Zsolt Nagy, Szabolcs Kosztolányi, László Váróczy, Márk Plander, Tamás Schneider, Judit Demeter, Hussain Alizadeh, Árpád Illés, Tamás Masszi, Gábor Mikala. Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime. Orvosi hetilap. 2021 09; 162(36):1451-1458. doi: 10.1556/650.2021.32179. [PMID: 34482291]
  • Naveed Pervaiz, Harjot Kaur, Davinder Parsad, Ravinder Kumar. Immune-modulatory effects of lenalidomide inhibited the progression of lesions in a vitiligo mouse model. Pigment cell & melanoma research. 2021 09; 34(5):918-927. doi: 10.1111/pcmr.12962. [PMID: 33522688]
  • Joseph M Tuscano, Christina Poh, Paul Kaesberg, Guilluame Luxardi, Alexander Merleev, Alina Marusina, Ann Brunson, Aaron Rosenberg, Brian Jonas, Emanual Maverakis. Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 09; 27(17):4726-4736. doi: 10.1158/1078-0432.ccr-20-4622. [PMID: 34088724]
  • Jack Khouri, Megan Nakashima, Sandy Wong. Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome: A Review. JAMA oncology. 2021 Sep; 7(9):1383-1391. doi: 10.1001/jamaoncol.2021.0586. [PMID: 34081097]
  • María José Cejalvo, Gabriela Bustamante, Esther González, Judith Vázquez-Álvarez, Ricarda García, Ángel Ramírez-Payer, Ernesto Pérez-Persona, Eugenia Abella, Sebastián Garzón, Antoni García, Isidro Jarque, Marta Sonia González, Antonia Sampol, Cristina Motlló, Josep María Martí, Magdalena Alcalá, Rafael Duro, Yolanda González, José Luis Sastre, Josep Sarrà, Giselle Lostaunau, Rocío López, Javier de la Rubia. Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma. Annals of hematology. 2021 Jul; 100(7):1769-1778. doi: 10.1007/s00277-021-04529-5. [PMID: 33885924]
  • Adrian Duek, Batia Kaplan, Yafit Segman, Merav Leiba. Multiple Myeloma with Systemic Amyloidosis: Serum Free Light Chain Dimerization Analysis in the Diagnosis of an Equivocal Case of Plasma Cell Dyscrasia. The Israel Medical Association journal : IMAJ. 2021 Jul; 23(7):459-461. doi: NULL. [PMID: 34251134]
  • Jayna Mistry, Vidhya Murthy, Hannah Giles, Zbigniew Rudzki. Spindle cell morphology in myeloma. British journal of haematology. 2021 06; 193(5):861. doi: 10.1111/bjh.17349. [PMID: 33655489]
  • Qian-Qian Cai, Xue-Min Gao, Jing Le, Hao Zhao, Hao Cai, Xin-Xin Cao, Jian Li. Cereblon expression is a prognostic marker in newly diagnosed POEMS syndrome treated with lenalidomide plus dexamethasone. Annals of hematology. 2021 Jun; 100(6):1547-1552. doi: 10.1007/s00277-021-04517-9. [PMID: 33839882]
  • Siyuan Su, Jianfeng Chen, Ying Wang, Lilly M Wong, Zhichuan Zhu, Guochun Jiang, Pengda Liu. Lenalidomide downregulates ACE2 protein abundance to alleviate infection by SARS-CoV-2 spike protein conditioned pseudoviruses. Signal transduction and targeted therapy. 2021 05; 6(1):182. doi: 10.1038/s41392-021-00608-1. [PMID: 33972500]
  • Radowan A Elnair, Sarah A Holstein. Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma. Drugs. 2021 May; 81(7):825-840. doi: 10.1007/s40265-021-01514-0. [PMID: 33871818]
  • Bernard Regidor, Regina Swift, Benjamin Eades, Marsiye Emamy-Sadr, Fadi Tarhini, Tanya M Spektor, James R Berenson. Frequent occurrence of hypophosphatemia among multiple myeloma patients treated with elotuzumab: a single clinic retrospective study. Annals of hematology. 2021 Apr; 100(4):1079-1085. doi: 10.1007/s00277-020-04351-5. [PMID: 33237342]
  • Alan F List, Zhuoxin Sun, Amit Verma, John M Bennett, Rami S Komrokji, Kathy McGraw, Jaroslaw Maciejewski, Jessica K Altman, Puneet S Cheema, David F Claxton, Selina M Luger, Ryan J Mattison, Timothy R Wassenaar, Andrew S Artz, Charles A Schiffer, Mark R Litzow, Martin S Tallman. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 03; 39(9):1001-1009. doi: 10.1200/jco.20.01691. [PMID: 33439748]
  • Yael C Cohen, Mor Zada, Shuang-Yin Wang, Chamutal Bornstein, Eyal David, Adi Moshe, Baoguo Li, Shir Shlomi-Loubaton, Moshe E Gatt, Chamutal Gur, Noa Lavi, Chezi Ganzel, Efrat Luttwak, Evgeni Chubar, Ory Rouvio, Iuliana Vaxman, Oren Pasvolsky, Mouna Ballan, Tamar Tadmor, Anatoly Nemets, Osnat Jarchowcky-Dolberg, Olga Shvetz, Meirav Laiba, Ofer Shpilberg, Najib Dally, Irit Avivi, Assaf Weiner, Ido Amit. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nature medicine. 2021 03; 27(3):491-503. doi: 10.1038/s41591-021-01232-w. [PMID: 33619369]
  • Smith Giri, Peter Barth, Luciano J Costa, Adam J Olszewski. Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis. Journal of geriatric oncology. 2021 03; 12(2):256-261. doi: 10.1016/j.jgo.2020.07.007. [PMID: 32684352]
  • Holly Lee, Jason Tay, Peter Duggan, Sylvia McCulloch, Paola Neri, Nizar J Bahlis, Victor H Jimenez-Zepeda. The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience. European journal of haematology. 2021 Mar; 106(3):340-345. doi: 10.1111/ejh.13552. [PMID: 33197297]
  • Alessandra Romano, Marco Santoro, Concetta Conticello, Sergio Siragusa, Francesco DI Raimondo, Giovanni Martinelli, Claudio Cerchione. Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma. Panminerva medica. 2021 Mar; 63(1):13-20. doi: 10.23736/s0031-0808.20.04141-5. [PMID: 32955184]
  • Mohammed Isaac Abu Zaanona, Priyank Patel. Plasma cell leukaemia with t(11;14) not responsive to venetoclax. BMJ case reports. 2021 Jan; 14(1):. doi: 10.1136/bcr-2020-238641. [PMID: 33495184]
  • Marco Cippitelli, Helena Stabile, Andrea Kosta, Sara Petillo, Angela Gismondi, Angela Santoni, Cinzia Fionda. Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them. International journal of molecular sciences. 2021 Jan; 22(3):. doi: 10.3390/ijms22031103. [PMID: 33499314]
  • Susanne Ghandili, Katja C Weisel, Carsten Bokemeyer, Lisa Beatrice Leypoldt. Current Treatment Approaches to Newly Diagnosed Multiple Myeloma. Oncology research and treatment. 2021; 44(12):690-699. doi: 10.1159/000520504. [PMID: 34784608]
  • Maki Oku, Ryo Ishino, Shumpei Uchida, Osamu Imataki, Naoshi Sugimoto, Tomoki Todo, Norimitsu Kadowaki. Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms. British journal of haematology. 2021 01; 192(2):343-353. doi: 10.1111/bjh.17173. [PMID: 33216988]
  • Yajuan Gao, Shiyu Zhang, Lu Yang, Jian Li, Yuehua Liu, Tao Wang. Skin Responses in Newly Diagnosed Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome After Therapy With Low-Dose Lenalidomide Plus Dexamethasone. Frontiers in immunology. 2021; 12(?):681360. doi: 10.3389/fimmu.2021.681360. [PMID: 34025681]
  • Peter Barth, Smith Giri, John L Reagan, Adam J Olszewski. Outcomes of lenalidomide- or bortezomib-based regimens in older patients with plasma cell myeloma. American journal of hematology. 2021 01; 96(1):14-22. doi: 10.1002/ajh.25996. [PMID: 32918301]
  • Saad Z Usmani, Antje Hoering, Sikander Ailawadhi, Rachael Sexton, Brea Lipe, Sandi Fredette Hita, Jason Valent, Michael Rosenzweig, Jeffrey A Zonder, Madhav Dhodapkar, Natalie Callander, Todd Zimmerman, Peter M Voorhees, Brian Durie, S Vincent Rajkumar, Paul G Richardson, Robert Z Orlowski. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. The Lancet. Haematology. 2021 Jan; 8(1):e45-e54. doi: 10.1016/s2352-3026(20)30354-9. [PMID: 33357482]
  • Jack Khouri, Beth M Faiman, Dale Grabowski, Reda Z Mahfouz, Shahper N Khan, Wei Wei, Jason Valent, Robert Dean, Christy Samaras, Babal K Jha, Hillard Lazarus, Erica L Campagnaro, Ehsan Malek, Janice Reed, Mary Ann Karam, Kimberly Hamilton, Sherry Fada, Matt Kalaycio, Hien Liu, Ronald Sobecks, Yogen Saunthararajah, Yap Chew, Mohammed Orloff, Frederic J Reu. DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Seminars in hematology. 2021 01; 58(1):45-55. doi: 10.1053/j.seminhematol.2020.12.004. [PMID: 33509443]
  • Irena Misiewicz-Krzeminska, Cristina de Ramón, Luis A Corchete, Patryk Krzeminski, Elizabeta A Rojas, Isabel Isidro, Ramón García-Sanz, Joaquín Martínez-López, Albert Oriol, Joan Bladé, Juan-José Lahuerta, Jesús San Miguel, Laura Rosiñol, María-Victoria Mateos, Norma C Gutiérrez. Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. Blood advances. 2020 12; 4(23):6023-6033. doi: 10.1182/bloodadvances.2020002711. [PMID: 33284947]
  • Katharina Helene Susek, Charlotte Gran, Hans-Gustaf Ljunggren, Evren Alici, Hareth Nahi. Outcome of COVID-19 in multiple myeloma patients in relation to treatment. European journal of haematology. 2020 Dec; 105(6):751-754. doi: 10.1111/ejh.13502. [PMID: 32745304]
  • Thomas S Y Chan, Alvin H W Ip, Rex Au-Yeung, Annie W K Pang, Yok-Lam Kwong. Unique evolution of angioimmunoblastic T cell lymphoma to Epstein-Barr virus-positive plasma cell myeloma. Annals of hematology. 2020 Dec; 99(12):2949-2952. doi: 10.1007/s00277-020-04110-6. [PMID: 32514627]
  • Yasuo Kusunoki, Tomoko Namba-Hamano, Tsunayuki Kakimoto, Satoko Yamamoto, Natsuko Ikeda, Keiko Wakabayashi, Kumie Teramoto, Masanobu Takeji. A case of proliferative glomerulonephritis with immunoglobulin A1-lambda deposits successfully treated by chemotherapy. CEN case reports. 2020 11; 9(4):326-332. doi: 10.1007/s13730-020-00480-y. [PMID: 32350770]
  • Yoshihito Horisawa, Tadakazu Kondo, Masakatsu Hishizawa, Kouhei Yamashita, Akifumi Takaori-Kondo. A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab. Annals of hematology. 2020 Nov; 99(11):2699-2701. doi: 10.1007/s00277-020-04029-y. [PMID: 32318778]
  • Jing Li, Li Bao, Zhongjun Xia, Sili Wang, Xin Zhou, Kaiyang Ding, Wenhao Zhang, Wei Yang, Bingzong Li, Chengcheng Fu, Bing Chen, Luoming Hua, Liang Wang, Jun Luo, Yang Yang, Tianhong Xu, Weida Wang, Yun Huang, Guolin Wu, Peng Liu. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. Annals of hematology. 2020 Nov; 99(11):2589-2598. doi: 10.1007/s00277-020-04234-9. [PMID: 32892275]
  • Xiaofeng Shi, Jiannong Wu, Qian Jiang, Shuo Zhang, Wanru Chen, Xianqiu Yu, Yichen Liu, Min Chen, Jie Peng, Tiantian Li, Yan Zhu, Xiaodong Xi. Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient: A case report. Medicine. 2020 Oct; 99(44):e22931. doi: 10.1097/md.0000000000022931. [PMID: 33126356]
  • Katarzyna A Jalowiec, Martin Andres, Behrouz Mansouri Taleghani, Albulena Musa, Martina Dickenmann, Anne Angelillo-Scherrer, Alicia Rovó, Johanna A Kremer Hovinga. Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature. Journal of medical case reports. 2020 Oct; 14(1):206. doi: 10.1186/s13256-020-02505-7. [PMID: 33121522]
  • Miyuki Okura, Naoko Ida, Takahiro Yamauchi. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era. Medical oncology (Northwood, London, England). 2020 Oct; 37(11):103. doi: 10.1007/s12032-020-01423-4. [PMID: 33068194]
  • Samantha Hinsley, Katrina Walker, Debbie Sherratt, Lucy Bailey, Sadie Reed, Louise Flanagan, Sophie McKee, Fiona Brudenell Straw, Bryony Dawkins, David Meads, Holger W Auner, Martin F Kaiser, Mark Cook, Sarah Brown, Gordon Cook. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. Trials. 2020 Oct; 21(1):826. doi: 10.1186/s13063-020-04739-8. [PMID: 33008427]
  • Shaji K Kumar, Susanna J Jacobus, Adam D Cohen, Matthias Weiss, Natalie Callander, Avina K Singh, Terri L Parker, Alexander Menter, Xuezhong Yang, Benjamin Parsons, Pankaj Kumar, Prashant Kapoor, Aaron Rosenberg, Jeffrey A Zonder, Edward Faber, Sagar Lonial, Kenneth C Anderson, Paul G Richardson, Robert Z Orlowski, Lynne I Wagner, S Vincent Rajkumar. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet. Oncology. 2020 10; 21(10):1317-1330. doi: 10.1016/s1470-2045(20)30452-6. [PMID: 32866432]
  • Hikmettullah Batgi, Mehmet Sinan Dal, Alparslan Merdin, Merih Kızıl Çakar, Tuğçe Nur Yiğenoğlu, Fevzi Altuntaş. A multiple myeloma patient who developed ischemic colitis during lenalidomide treatment: A rare case report. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2020 Sep; 26(6):1499-1500. doi: 10.1177/1078155219900910. [PMID: 32028837]
  • Sean J Hipp, Stewart Goldman, Aradhana Kaushal, Andra Krauze, Deborah Citrin, John Glod, Kim Walker, Joanna H Shih, Hema Sethumadhavan, Keith O'Neill, James H Garvin, Julia Glade-Bender, Matthias A Karajannis, Mark P Atlas, Arman Odabas, Louis T Rodgers, Cody J Peer, Jason Savage, Kevin A Camphausen, Roger J Packer, W Douglas Figg, Katherine E Warren. A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. Journal of neuro-oncology. 2020 Sep; 149(3):437-445. doi: 10.1007/s11060-020-03627-0. [PMID: 33040274]
  • Go Woon Kim, Jung Yoo, Hye-Rim Won, Soo-Keun Yeon, Sang Woo Lee, Dong Hoon Lee, Yu Hyun Jeon, So Hee Kwon. A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma. Leukemia research. 2020 08; 95(?):106398. doi: 10.1016/j.leukres.2020.106398. [PMID: 32512378]
  • Jianxuan Zou, Richard J Jones, Hua Wang, Isere Kuiatse, Fazal Shirazi, Elisabet E Manasanch, Hans C Lee, Robert Sullivan, Leah Fung, Normand Richard, Paul Erdman, Eduardo Torres, David Hecht, Imelda Lam, Brooke McElwee, Aparajita H Chourasia, Kyle W H Chan, Frank Mercurio, David I Stirling, Robert Z Orlowski. The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance. Journal of molecular medicine (Berlin, Germany). 2020 08; 98(8):1161-1173. doi: 10.1007/s00109-020-01943-6. [PMID: 32632752]
  • Cynthia Ciwei Lim, Khin Zar Li Lwin, May Anne Cheong, Kamaraj Kanagasabapathy, Chandramouli Nagarajan, Alwin Loh. An unusual cause of renal tubular dysfunction in multiple myeloma. International urology and nephrology. 2020 Aug; 52(8):1603-1605. doi: 10.1007/s11255-020-02504-z. [PMID: 32451782]
  • Haya Abdulkarim, Mohammed Zourob, Mohamed Siaj. Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide. Scientific reports. 2020 06; 10(1):10424. doi: 10.1038/s41598-020-67241-w. [PMID: 32591583]
  • Michele Cavo, Francesca Gay, Meral Beksac, Lucia Pantani, Maria Teresa Petrucci, Meletios A Dimopoulos, Luca Dozza, Bronno van der Holt, Sonja Zweegman, Stefania Oliva, Vincent H J van der Velden, Elena Zamagni, Giuseppe A Palumbo, Francesca Patriarca, Vittorio Montefusco, Monica Galli, Vladimir Maisnar, Barbara Gamberi, Markus Hansson, Angelo Belotti, Ludek Pour, Paula Ypma, Mariella Grasso, Alexsandra Croockewit, Stelvio Ballanti, Massimo Offidani, Iolanda D Vincelli, Renato Zambello, Anna Marina Liberati, Niels Frost Andersen, Annemiek Broijl, Rossella Troia, Anna Pascarella, Giulia Benevolo, Mark-David Levin, Gerard Bos, Heinz Ludwig, Sara Aquino, Anna Maria Morelli, Ka Lung Wu, Rinske Boersma, Roman Hajek, Marc Durian, Peter A von dem Borne, Tommaso Caravita di Toritto, Thilo Zander, Christoph Driessen, Giorgina Specchia, Anders Waage, Peter Gimsing, Ulf-Henrik Mellqvist, Marinus van Marwijk Kooy, Monique Minnema, Caroline Mandigers, Anna Maria Cafro, Angelo Palmas, Susanna Carvalho, Andrew Spencer, Mario Boccadoro, Pieter Sonneveld. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. The Lancet. Haematology. 2020 Jun; 7(6):e456-e468. doi: 10.1016/s2352-3026(20)30099-5. [PMID: 32359506]
  • Yao Wang, Haiyue Zhang, Qian Chen, Fangzhou Jiao, Chunxia Shi, Maohua Pei, Jian Lv, Hong Zhang, Luwen Wang, Zuojiong Gong. TNF-α/HMGB1 inflammation signalling pathway regulates pyroptosis during liver failure and acute kidney injury. Cell proliferation. 2020 Jun; 53(6):e12829. doi: 10.1111/cpr.12829. [PMID: 32419317]
  • Ling-Shan Liu, Xiao Zhang, Hao Zhao, Xue-Min Gao, Dao-Bin Zhou, Rong-Ping Dai, Jian Li. Reliability of optic disc edema area in estimating the severity of papilledema in patients with POEMS syndrome. Orphanet journal of rare diseases. 2020 05; 15(1):116. doi: 10.1186/s13023-020-01392-x. [PMID: 32429967]
  • Evangelos Terpos, Karthik Ramasamy, Nadjoua Maouche, Jiri Minarik, Ioannis Ntanasis-Stathopoulos, Eirini Katodritou, Matthew W Jenner, Hana Plonkova, Maria Gavriatopoulou, Grant D Vallance, Tomas Pika, Maria Kotsopoulou, Jaimal Kothari, Tomas Jelinek, Efstathios Kastritis, Robin Aitchison, Meletios A Dimopoulos, Athanasios Zomas, Roman Hajek. Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma. Annals of hematology. 2020 May; 99(5):1049-1061. doi: 10.1007/s00277-020-03981-z. [PMID: 32236735]
  • Albert Oriol. A critical evaluation of pembrolizumab in addition to lenalidomide and dexamethasone for the treatment of multiple myeloma. Expert review of hematology. 2020 05; 13(5):435-445. doi: 10.1080/17474086.2020.1744432. [PMID: 32182438]
  • Teruhito Takakuwa, Taku Araki, Koji Nakamura, Tomoko Fukuyama, Akiko Miura, Yotaro Fujitani, Akari Hisanabe, Anna Kaieda, Erina Fukada, Ryosuke Yamamura. Morphologic Classification Is an Important Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib or Lenalidomide. Annals of clinical and laboratory science. 2020 May; 50(3):333-341. doi: NULL. [PMID: 32581022]
  • Tomoki Suichi, Sonoko Misawa, Kengo Nagashima, Yasunori Sato, Yuta Iwai, Kanako Katayama, Yukari Sekiguchi, Kazumoto Shibuya, Hiroshi Amino, Yo-Ichi Suzuki, Atsuko Tsuneyama, Keigo Nakamura, Satoshi Kuwabara. Lenalidomide Treatment for Thalidomide-refractory POEMS Syndrome: A Prospective Single-arm Clinical Trial. Internal medicine (Tokyo, Japan). 2020 May; 59(9):1149-1153. doi: 10.2169/internalmedicine.3800-19. [PMID: 32009091]
  • Thibault Mahévas, Bertrand Arnulf, Jean-David Bouaziz, Cristina Bulai Livideanu, Amélie Osio, Amandine Servy, Bernard Cribier, Bruno Sassolas, Marie Jachiet, Laurence Michel, Pierre Aucouturier, Dan Lipsker, Camille Frances, Emilie Sbidian, Michel Rybojad, Vincent Descamps, Michel D'Incan, Philippe Humbert, Marie Beylot-Barry, Thierry Passeron, Claire de Moreuil, Ruba Y Taha, Olivier Hermine, Alain Dupuy, Sébastien Barbarot, Sébastien Debarbieux, Olivier Carpentier, Fanny Brault, Jean-Luc Schmutz, Domitille Thomas-Beaulieu, Philippe Modiano, Charles Zarnitsky, François Lifermann, Emilie Baubion, Nicolas Limal, Fabien Le Bras, Marie Le Moigne, Marie Tauber, Alexis Talbot, Romain Prud'homme, Sandy Peltier, Adèle De Masson, Maxime Battistella, Martine Bagot, Arsène Mékinian, Olivier Fain. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema. Blood. 2020 04; 135(14):1101-1110. doi: 10.1182/blood.2019002300. [PMID: 32027747]
  • Sonia Morè, Laura Corvatta, Laura Maracci, Benedetta Costantini, Attilio Olivieri, Massimo Offidani. Developments in consolidation and maintenance strategies in post-remission multiple myeloma. Expert review of hematology. 2020 04; 13(4):351-362. doi: 10.1080/17474086.2020.1739517. [PMID: 32162982]
  • Manon Sapet, Ludovic Fouillet, Elisabeth Daguenet, Blandine Laurent, Denis Guyotat, Caroline Le Jeune. [Proteinuria in multiple myeloma: Be careful to iatrogeny]. Bulletin du cancer. 2020 Apr; 107(4):519-520. doi: 10.1016/j.bulcan.2020.01.014. [PMID: 32178835]
  • Giulia Palazzo. [Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.]. Recenti progressi in medicina. 2020 Mar; 111(3):160-166. doi: 10.1701/3315.32858. [PMID: 32157264]
  • Chutima Kunacheewa, Elisabet E Manasanch. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. Best practice & research. Clinical haematology. 2020 03; 33(1):101152. doi: 10.1016/j.beha.2020.101152. [PMID: 32139017]
  • Sydney X Lu. Modern treatments and future directions for newly diagnosed multiple myeloma patients. Best practice & research. Clinical haematology. 2020 03; 33(1):101151. doi: 10.1016/j.beha.2020.101151. [PMID: 32139016]
  • Shin Ohara, Shiro Ide, Tomoyuki Uchida, Morihiro Inoue, Jian Hua, Masao Hagihara. [Multiple myeloma with light chain deposition disease showing needle-like crystal inclusions in plasma cells and macrophages in multiple organs]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2020; 61(11):1620-1624. doi: 10.11406/rinketsu.61.1620. [PMID: 33298657]
  • Sophie Park, Charikleia Kelaidi, Mathieu Meunier, Nicole Casadevall, Aaron T Gerds, Uwe Platzbecker. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. Annals of hematology. 2020 Jan; 99(1):7-19. doi: 10.1007/s00277-019-03799-4. [PMID: 31650290]
  • Wataru Takahashi, Motoshi Ichikawa, Akihito Okazaki, Fumi Nakamura, Honoka Arai, Tomoyuki Handa, Yuko Nakamura, Yuka Nakamura, Sachiko Seo, Ko Sasaki, Kinuko Mitani. [Effective treatment of POEMS syndrome accompanied by plasmacytoma with lenalidomide, dexamethasone, and local irradiation]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2020; 61(3):262-267. doi: 10.11406/rinketsu.61.262. [PMID: 32224588]
  • Andrew T Stefka, David Johnson, Shaun Rosebeck, Jae-Hyun Park, Yusuke Nakamura, Andrzej J Jakubowiak. Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. Cancer medicine. 2020 01; 9(1):324-334. doi: 10.1002/cam4.2695. [PMID: 31714026]
  • Yoko Kado, Masayuki Tsujimoto, Shin-Ichi Fuchida, Akira Okano, Mayumi Hatsuse, Satoshi Murakami, Hikofumi Sugii, Kumi Ueda, Yuki Toda, Tetsuya Minegaki, Kohshi Nishiguchi, Yuichi Muraki, Chihiro Shimazaki, Eishi Ashihara. Factors Associated with Dose Modification of Lenalidomide Plus Dexamethasone Therapy in Multiple Myeloma. Biological & pharmaceutical bulletin. 2020; 43(8):1253-1258. doi: 10.1248/bpb.b20-00337. [PMID: 32741946]
  • Jiro Kikuchi, Yusuke Furukawa. [Toll-like receptor CD180 and the bone marrow microenvironment as therapeutic targets in multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2020; 61(7):832-841. doi: 10.11406/rinketsu.61.832. [PMID: 32759572]
  • Akihide Nakamura, Tomohiro Yamaguchi, Ryugo Ito, Keiki Kawakami. [Successful disease control of plasma cell leukemia by the treatment comprising proteasome inhibitors, followed by daratumumab, lenalidomide, and dexamethasone therapy]. [Rinsho ketsueki] The Japanese journal of clinical hematology. 2020; 61(11):1600-1604. doi: 10.11406/rinketsu.61.1600. [PMID: 33298653]
  • Sho Ikeda, Takahiro Kobayashi, Masaya Saito, Atsushi Komatsuda, Kumi Ubukawa, Yoshihiro Kameoka, Naoto Takahashi. Multiparameter Flow Cytometry for the Identification of Neoplastic Plasma Cells in POEMS Syndrome with IgG-kappa Gammopathy: Successful Treatment Using Lenalidomide and Dexamethasone. Internal medicine (Tokyo, Japan). 2019 Dec; 58(23):3461-3468. doi: 10.2169/internalmedicine.2882-19. [PMID: 31391391]
  • Alanna C Green, Darren Lath, Katie Hudson, Brant Walkley, Jennifer M Down, Robert Owen, Holly R Evans, Julia Paton-Hough, Gwendolen C Reilly, Michelle A Lawson, Andrew D Chantry. TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2019 12; 34(12):2311-2326. doi: 10.1002/jbmr.3859. [PMID: 31442332]
  • Ryan B Sinit, Dick G Hwang, Prakash Vishnu, Jess F Peterson, David M Aboulafia. B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review. BMC cancer. 2019 Nov; 19(1):1147. doi: 10.1186/s12885-019-6286-9. [PMID: 31775673]
  • Jim H Hughes, Richard N Upton, Stephanie E Reuter, Darlene M Rozewski, Mitch A Phelps, David J R Foster. Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice. Cancer chemotherapy and pharmacology. 2019 11; 84(5):1073-1087. doi: 10.1007/s00280-019-03941-z. [PMID: 31493176]
  • Szilvia Lovas, Gergely Varga, Péter Farkas, Tamás Masszi, Nikolett Wohner, Ágnes Bereczki, Nóra Adamkovich, Zita Borbényi, Árpád Szomor, Hussain Alizadeh, Erika Szaleczky, Krisztina Wolf, Tamás Schneider, Márk Plander, Tamás Szendrei, Ottó Csacsovszki, Zoltán Csukly, Péter Rajnics, Miklós Egyed, Zsolt Nagy, László Rejtő, Árpád Illés, Gábor Mikala, László Váróczy. Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients. International journal of hematology. 2019 Nov; 110(5):559-565. doi: 10.1007/s12185-019-02715-w. [PMID: 31392600]
  • Efstathios Kastritis, Ioanna Dialoupi, Maria Gavriatopoulou, Maria Roussou, Nikolaos Kanellias, Despina Fotiou, Ioannis Ntanasis-Stathopoulos, Elektra Papadopoulou, Dimitrios C Ziogas, Kimon Stamatelopoulos, Efstathios Manios, Argyrios Ntalianis, Evangelos Eleutherakis-Papaiakovou, Asimina Papanikolaou, Magdalini Migkou, Aristea-Maria Papanota, Harikleia Gakiopoulou, Erasmia Psimenou, Maria Irini Tselegkidi, Ourania Tsitsilonis, Ioannis Kostopoulos, Evangelos Terpos, Meletios A Dimopoulos. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. Blood advances. 2019 10; 3(20):3002-3009. doi: 10.1182/bloodadvances.2019000147. [PMID: 31648323]
  • Samuel Benjamin Reynolds, Dhaval Pravinkumar Maghavani, Hamza Hashmi. Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis. BMJ case reports. 2019 Sep; 12(9):. doi: 10.1136/bcr-2019-230249. [PMID: 31527206]
  • Susanna Gassiot, Yolanda González, Mireia Morgades, Cristina Motlló, Victòria Clapés, Clara Maluquer, Gladys Ibarra, Laura Abril, Josep-Maria Ribera, Albert Oriol. Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?. Clinical lymphoma, myeloma & leukemia. 2019 09; 19(9):585-592.e1. doi: 10.1016/j.clml.2019.05.020. [PMID: 31255588]
  • Yumi Takahashi, Hiroyuki Iwano, Ippei Nakano, Arata Fukushima, Masanao Naya, Ai Shimizu, Yoshihiro Matsuno, Noriko Oyama-Manabe, Toshihisa Anzai. POEMS Syndrome Showing Left Ventricular Dysfunction and Extracellular Edema Assessed by Cardiac Magnetic Resonance Imaging. Internal medicine (Tokyo, Japan). 2019 Sep; 58(17):2539-2543. doi: 10.2169/internalmedicine.2842-19. [PMID: 31118405]
  • Roland Christian Schelker, Matthias Grube, Albrecht Reichle, Beate Wagner, Wolfgang Herr, Matthias Evert, Martin Vogelhuber. Detection of hemophagocytic extremely multinucleated giant plasma cells after rituximab/low-dose lenalidomide treatment in CD20+ multiple myeloma. Leukemia & lymphoma. 2019 09; 60(9):2331-2333. doi: 10.1080/10428194.2019.1571200. [PMID: 30721106]
  • Jonathan M Harnoss, Adrien Le Thomas, Anna Shemorry, Scot A Marsters, David A Lawrence, Min Lu, Yung-Chia Ariel Chen, Jing Qing, Klara Totpal, David Kan, Ehud Segal, Mark Merchant, Mike Reichelt, Heidi Ackerly Wallweber, Weiru Wang, Kevin Clark, Susan Kaufman, Maureen H Beresini, Steven T Laing, Wendy Sandoval, Maria Lorenzo, Jiansheng Wu, Justin Ly, Tom De Bruyn, Amy Heidersbach, Benjamin Haley, Alvin Gogineni, Robby M Weimer, Dong Lee, Marie-Gabrielle Braun, Joachim Rudolph, Michael J VanWyngarden, Daniel W Sherbenou, Patricia Gomez-Bougie, Martine Amiot, Diego Acosta-Alvear, Peter Walter, Avi Ashkenazi. Disruption of IRE1α through its kinase domain attenuates multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America. 2019 08; 116(33):16420-16429. doi: 10.1073/pnas.1906999116. [PMID: 31371506]
  • Yaohua Cao, Ning Wan, Zhuoru Liang, Jingmei Xie, Sen Wang, Tengfei Lin, Tiantian Zhang, Jie Jiang. Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis. Clinical lymphoma, myeloma & leukemia. 2019 08; 19(8):e478-e488. doi: 10.1016/j.clml.2019.04.009. [PMID: 31130487]